News
OTLK
1.090
0.00%
0.000
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), BioNano Genomics (BNGO)
TipRanks · 03/14 04:20
BRIEF-Outlook Therapeutics Confirms It Has No Exposure To Silicon Valley Bank
Reuters · 03/13 11:41
Outlook Therapeutics (OTLK) Investor Presentation - Slideshow
Seeking Alpha · 02/17 19:16
H.C. Wainwright Reaffirms Their Buy Rating on Outlook Therapeutics (OTLK)
TipRanks · 02/15 11:25
HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Maintains $5 Price Target
Benzinga · 02/15 11:14
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Cullinan Management (CGEM)
TipRanks · 02/15 06:50
Outlook Therapeutics GAAP EPS of -$0.08
Seeking Alpha · 02/14 13:30
BRIEF-Outlook Therapeutics Reports Financial Results For First Quarter Fiscal Year 2023
Reuters · 02/14 13:29
Outlook Therapeutics Q1 EPS $(0.08) Misses $(0.04) Estimate
Benzinga · 02/14 13:24
Outlook draws bullish views at Cantor on potential FDA nod for lead asset
Seeking Alpha · 02/06 18:35
SPCE, AI and EXPR are among pre market gainers
Seeking Alpha · 02/06 13:31
Cantor Fitzgerald Initiates Coverage On Outlook Therapeutics with Overweight Rating, Announces Price Target of $4
Benzinga · 02/06 12:42
--Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target
--Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target
MT Newswires · 02/06 09:46
BRIEF-Outlook Therapeutics® Strengthens Medical Affairs And Commercial Expertise With Appointments Of Surendra Sharma, MD, Senior Vice President Of Medical Affairs And Glen Olsheim, Executive Director Of Commercial Excellence
Reuters · 01/19 14:00
HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Lowers Price Target to $5
Benzinga · 01/06 11:29
Outlook Therapeutics (OTLK) Receives a Buy from H.C. Wainwright
TipRanks · 01/06 11:15
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating
MT Newswires · 01/06 09:54
What's Next For Stocks After S&P 500 Wraps Roughest Year Since 2008?
Benzinga · 12/30/2022 21:09
Outlook Therapeutics GAAP EPS of -$0.31 in-line
Seekingalpha · 12/29/2022 14:45
Outlook Therapeutics Fiscal Year 2022 Net Loss Narrows
Outlook Therapeutics Fiscal Year 2022 Net Loss Narrows
MT Newswires · 12/29/2022 10:10
More
Webull provides a variety of real-time OTLK stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti- Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.